CyberArk Named a Leader in 2023 Gartner Magic Quadrant for Privileged Access Management
CyberArk (NASDAQ: CYBR), the identity security company, today announced it has been named a Leader in the 2023 Gartner® Magic Quadrant™ for Privileged Access Management.1 CyberArk is recognized in this report for the fifth consecutive time. Additionally, CyberArk is the only vendor positioned as a Leader in both Gartner Magic Quadrant Privileged Access Management (PAM) and Access Management 2 reports.
The CyberArk Identity Security Platform enables organizations to secure all identities – including workforce, IT, developer and non-human – against cyber threats with intelligent privilege controls. With CyberArk, customers have a single, unified platform for identity security that delivers operational efficiencies and faster ROI. Core to the platform are PAM solutions that secure standing, just-in-time and zero standing privileged access across hybrid and multi-cloud environments, and that improve secrets management to significantly reduce the #1 source of cyber risk: credential theft.
“We are extremely proud to be named a Leader by Gartner again. We believe this recognition underscores our commitment and track record of delivering continuous innovation to meet the evolving needs of our customers,” said Matt Cohen, CEO, CyberArk. “In today’s business and threat environment, every identity is a target for attackers. This is why we continue to extend intelligent privilege controls to all identities – human and machine – while developing deep product integrations across our platform, giving security teams the operational control and visibility they need to secure identities across the enterprise.”
CyberArk believes its consistent recognition as a Leader is the result of its focus on core foundational elements, including:
- Continuous Innovation: CyberArk continues to build upon core strengths in PAM and innovation across its PAM as-a-Service and self-hosted offerings. CyberArk has extended intelligent privilege controls across the entire identity lifecycle, for all types of identities. Recent innovations address emerging use cases for secure, developer-friendly access to public cloud workloads and services. New capabilities include just-in-time privileged access management and low-code and no-code automation workflows that enable automated identity orchestration. CyberArk Secrets Management, an essential part of PAM, is differentiated in its ability to allow organizations to centrally secure, manage and rotate secrets used by the broadest range of application identities. Earlier this year, CyberArk announced expanded secrets management capabilities, new AI-powered policy creation automation for improved endpoint privilege security and the ability for PAM administrators to broker, record and protect native privileged sessions in one-click.
- Exceptional Customer Experience: Globally, CyberArk provides flexible, closely aligned sales, technical and deployment resources to help customers accelerate time to value. Over the past year, CyberArk introduced new training programs and updates to the CyberArk Blueprint for Identity Security Success, in addition to ongoing complimentary access to resources such as the CyberArk Technical Community and CyberArk Success Blog. According to Gartner Peer Insights™, CyberArk has a 91% “would recommend” rating.3
- High Performance and Delivery: CyberArk Security Services, together with its global partner network of channel, MSPs, global systems integrators and advisory firms, help many of the world’s largest enterprises design, deploy and optimize PAM and identity security programs. CyberArk continues to nurture strong and consistent growth among its partner community through expanded training and enablement programs. Now, more than ever, CyberArk’s global ecosystem of C3 Alliance technology partners is critical to helping security teams consolidate and maximize existing investments to mitigate emerging risks and address evolving identity security challenges.
To download a complimentary copy of the 2023 Gartner Magic Quadrant for Privileged Access Management visit: https://www.cyberark.com/gartner-2023-mq-pam
1 – Gartner® Magic Quadrant™ for Privileged Access Management, by Felix Gaehtgens, James Hoover, Michael Kelley, Brian Guthrie, Abhyuday Data, 5 September 2023
2 – Gartner® Magic Quadrant for Access Management, by Henrique Teixeira, Abhyuday Data, Michael Kelley, James Hoover, Brian Guthrie, 1 November 2022
3 – Gartner Peer Insights™ (rating as of Aug. 30, 2023; based on past 12 months), https://www.gartner.com/reviews/market/privileged-access-management/vendor/cyberark
Gartner Disclaimers
GARTNER is a registered trademark and service mark of Gartner and Magic Quadrant and Peer Insights are a registered trademark, of Gartner, Inc. and/or its affiliates in the U.S. and internationally and are used herein with permission. All rights reserved.
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences with the vendors listed on the platform, should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
About CyberArk
CyberArk (NASDAQ: CYBR) is the global leader in identity security. Centered on intelligent privilege controls, CyberArk provides the most comprehensive security offering for any identity – human or machine – across business applications, distributed workforces, hybrid cloud environments and throughout the DevOps lifecycle. The world’s leading organizations trust CyberArk to help secure their most critical assets. To learn more about CyberArk, visit https://www.cyberark.com, read the CyberArk blogs or follow on LinkedIn, Twitter, Facebook or YouTube.
Copyright © 2023 CyberArk Software. All Rights Reserved. All other brand names, product names, or trademarks belong to their respective holders.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230911021116/en/
Contact information
Media Contacts:
Carissa Ryan, CyberArk
Email: press@cyberark.com
Highwire PR
Email: cyberark@highwirepr.com
Investor Relations:
Erica Smith, CyberArk
Email: ir@cyberark.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom